MOTS-C

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a 16-amino-acid mitochondrial-derived peptide that enhances metabolic homeostasis through AMPK activation.

Profile · 01

Overview

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a 16-amino-acid mitochondrial-derived peptide that enhances metabolic homeostasis through AMPK activation. Discovered in 2015, endogenous MOTS-C levels increase dramatically with exercise and decline with age. It is not FDA-approved for any indication. Preclinical models show improved insulin sensitivity, reduced obesity, and enhanced exercise capacity, though no human clinical trials have been completed. This protocol presents a once-daily subcutaneous approach using practical dilution for clear insulin-syringe measurements.

At a Glance

Goal
Enhance metabolic homeostasis, insulin sensitivity, and age-related physical performance
Categories
Metabolic HealthInsulin SensitivityFat OxidationAnti-AgingExercise Performance
Synergistic
Intermittent fasting protocols · Metformin (similar AMPK pathway) · NAD+ precursors
Profile · 02

Protocol

Suggested bi-weekly titration approach starting at 500 mcg and increasing to 2,000 mcg daily over 8 weeks.

Typical daily range
500–2,000 mcg once daily (gradual titration)
Start
500 mcg daily; increase by ~500 mcg every 2 weeks as tolerated
Target
1,500–2,000 mcg daily by Weeks 5–8
Frequency
Once per day (subcutaneous); morning preferred
Cycle Length
4–8 weeks on, followed by 4–8 weeks off
Timing
Morning administration preferred; rotate injection sites
Route
Subcutaneous
Cycle
4–8 weeks on, 4–8 weeks off

Inject once daily subcutaneously using the largest practical dilution to maintain measurement accuracy. At higher doses (2,000 mcg), volumes may require splitting into two injections at different sites. Dosing derives from preclinical metabolic models; no human clinical validation exists.

Dose progression

Weeks 1–2
500 mcg (0.5 mg)
Weeks 3–4
1,000 mcg (1.0 mg)
Weeks 5–6
1,500 mcg (1.5 mg)
Weeks 7–8
2,000 mcg (2.0 mg)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Science · 01

How MOTS-C works.

MOTS-C is a mitochondrial-derived peptide encoded within the 12S rRNA gene of mitochondrial DNA. It directly targets skeletal muscle and fat tissues to promote glucose uptake and fat oxidation. MOTS-C activates AMPK through inhibition of the folate cycle, causing accumulation of AICAR (an AMP analog), which shifts cells into an energy-efficient mode. Under metabolic stress, MOTS-C translocates to the nucleus to regulate nuclear gene expression, upregulating antioxidant pathways. Its actions resemble those of exercise and metformin at a cellular level. Mouse studies demonstrate prevention of diet-induced obesity and insulin resistance, improved exercise capacity in aged animals, and reduced age-related metabolic decline. No human clinical trials have been completed to date; a modified analog (CB4211) showed good tolerability in a Phase 1 trial.

Science · 02

Effects

Observations from clinical or preclinical literature.

Enhances insulin sensitivity and glucose metabolism in mouse models (preclinical data)
Increases fat oxidation and energy expenditure; prevents diet-induced obesity (animal studies)
Improves exercise capacity and counters age-related frailty (old mice ran 2x longer on treadmill tests)
May support cognitive function, bone formation, and immune modulation (preclinical, under investigation)
No severe adverse effects or organ toxicity observed in preclinical studies
Mild injection-site reactions (redness, inflammation, bruising) reported anecdotally
Theoretical downregulation risk with prolonged continuous use without cycling
Long-term human safety and efficacy remain unknown
Science · 03

Caution

Not approved by the FDA or other regulatory agencies for human use
No human clinical trials have been completed; all data are preclinical
Chronic continuous use beyond 8 weeks is uncharacterized; cycle appropriately
Not recommended during pregnancy or breastfeeding (no safety data available)
Discontinue use and consult a medical professional if concerning symptoms arise
Consult a healthcare provider before use if you have any chronic medical conditions

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

CoQ10 (Ubiquinone)
Supports mitochondrial electron transport chain function complementary to MOTS-C's metabolic actions.
Alpha-lipoic acid
Supports glucose metabolism and acts as a mitochondrial antioxidant.
B vitamins (especially B12 and folate)
Support the folate cycle that MOTS-C modulates through AMPK activation.
Magnesium
Essential cofactor for AMPK activity and over 300 enzymatic processes.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Pair with a balanced, protein-forward diet tailored to energy needs
Combine resistance training and aerobic activity to reinforce metabolic adaptations
Prioritize sleep (7–9 hours) and stress management to support hormonal balance
Consider intermittent fasting or caloric restriction for potential synergy with MOTS-C's AMPK-mediated effects
Time administration in the morning, ideally in a fasted state, to align with natural metabolic signaling
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Fasting glucose and insulin levels — monitor changes in insulin sensitivity and glucose regulation
  2. Body composition (weight, waist circumference, body fat %) — track fat reduction and lean mass changes
  3. Exercise capacity and endurance — monitor progressive improvements in physical performance
  4. Energy levels and recovery perception — subjective but informative markers of metabolic improvement
  5. Injection-site reactions — note any redness, swelling, or discomfort to guide site rotation
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

Fasting glucose and HbA1c
Primary markers of glucose metabolism and insulin sensitivity.
Fasting insulin and HOMA-IR
Assess insulin resistance directly relevant to MOTS-C's mechanism.
Lipid panel (LDL, HDL, triglycerides)
Monitor cardiovascular metabolic markers.
CMP (Comprehensive Metabolic Panel)
Assess liver and kidney function during peptide use.
CBC (Complete Blood Count)
Monitor overall health and rule out underlying conditions.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 10 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mcg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean vial stopper and skin with alcohol; allow to dry
Pinch a skinfold; insert needle at 45–90° into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily over 2–5 seconds
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy
Discard used syringes immediately in sharps container per WHO guidelines

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use new sterile insulin syringes for each injection; dispose in sharps container
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation
Inject slowly; wait a few seconds before withdrawing the needle
Document daily dose, injection time, and site rotation to maintain consistency
Allow refrigerated solution 5–10 minutes to reach room temperature before injection
MOTS-C is not approved by the FDA; clinical decisions should involve qualified healthcare providers
Reference · 02

References

  1. Cell Metabolism (2015)
    Lee C, Zeng J, Drew BG, et al., "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance".
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350682/
  2. Journal of Translational Medicine (2023)
    Wan W, Zhang L, Lin Y, et al., "Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging".
    https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-03885-2
  3. Nature Communications (2021)
    Reynolds JC, Lai RW, Woodhead JST, et al., "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline".
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817689/
  4. Cell Metabolism (2018)
    Kim KH, et al., "The mitochondrial-encoded peptide MOTS-c translocates to the nucleus under metabolic stress".
    https://pubmed.ncbi.nlm.nih.gov/29983246/
  5. Rapid Communications in Mass Spectrometry (2019)
    Knoop A, et al., "Development of an MS-based detection method for MOTS-c".
    https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/rcm.8337
  6. Cognitive Vitality Reports (2021)
    Alzheimer's Drug Discovery Foundation, "MOTS-c evidence review".
    https://www.alzdiscovery.org/uploads/cognitive_vitality_media/MOTS-c.pdf
  7. CDC
    "Vaccine administration: subcutaneous route technique".
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
  8. Subcutaneous Drug Injection Review (PMC)
    "Pharmacologic considerations of the subcutaneous route".
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/
On this page